Platelet Indices Altered in Severe Malaria
|
By LabMedica International staff writers Posted on 08 Jan 2014 |

Image: Photomicrograph shows a growing Plasmodium vivax trophozoite in a blood smear (Photo courtesy of the CDC - US Centers for Disease Control and Prevention).
Changes in platelet counts during acute malaria are common and such changes are a major cause of concern to clinicians because such cases are more likely to evolve into serious and complicated disease.
The reduction in the number of platelets, platelet function is also compromised in these patients suffering from acute malaria infection and this is generally evidenced by changes in the volume and other features of platelet cells.
Scientists at the University Hospital of Federal University of Mato Grosso (Cuiabá, Brazil) performed a cross-sectional descriptive study based on the clinical and laboratory data of 186 patients with acute malaria caused by Plasmodium vivax who attended the Malaria Clinic between 2008 and 2013. All the patients underwent hemogram and blood biochemical analyses at their first appointment and malaria was diagnosed on the basis of the microscopic examination of Giemsa-stained thick smears.
All blood cell counts were determined using the Pentra 80 automated equipment (Horiba Medical; Montpellier, France), which provides results for mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit (PCT). The normal ranges for MPV, PDW, and PCT provided for this equipment are 7.0/µm3–10.5/µm3, 11%–18%, and 0.15%–0.50% respectively. Patients with a longer duration of symptoms or those identified as primo infected were considered potential candidates for evolution into the severe form of malaria.
The MPV, PDW, and PCT values exhibited significant variability. A significant inverse relationship was observed between parasitaemia and PCT. Patients with warning signs for evolution into severe disease, with primo infection, or presenting with symptoms for over three days had the highest MPV and PDW. The mean platelet count was 114,823 ± 76,761 cells/mm3; 16.7% of the patients exhibited counts fewer than 50,000/mm3 and 60.7% had platelet counts between 50,000/mm3 and 150,000/mm3. The mean MPV was 9.3 µm, the mean PDW was 17.5% and mean PCT was 0.104%. Potentially more serious cases, that is, primo-infected patients, exhibited significantly higher MPV and PDW.
The authors concluded that that platelet indices were altered during acute and symptomatic infection by P. vivax. The elevation of MPV and PDW, and reduction of PCT are related to known potential risk factors for evolution into severe malaria, such as primo infection, longer symptom duration, and the presence of the classical warning signs of severe and complicated P. falciparum malaria. Therefore, these parameters and indices could be useful as predictors of severity in the clinical approach of patients with malaria caused by P. vivax. The study was published on December 27, 2013, in the Malaria Journal.
Related Links:
University Hospital of Federal University of Mato Grosso
Horiba Medical
The reduction in the number of platelets, platelet function is also compromised in these patients suffering from acute malaria infection and this is generally evidenced by changes in the volume and other features of platelet cells.
Scientists at the University Hospital of Federal University of Mato Grosso (Cuiabá, Brazil) performed a cross-sectional descriptive study based on the clinical and laboratory data of 186 patients with acute malaria caused by Plasmodium vivax who attended the Malaria Clinic between 2008 and 2013. All the patients underwent hemogram and blood biochemical analyses at their first appointment and malaria was diagnosed on the basis of the microscopic examination of Giemsa-stained thick smears.
All blood cell counts were determined using the Pentra 80 automated equipment (Horiba Medical; Montpellier, France), which provides results for mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit (PCT). The normal ranges for MPV, PDW, and PCT provided for this equipment are 7.0/µm3–10.5/µm3, 11%–18%, and 0.15%–0.50% respectively. Patients with a longer duration of symptoms or those identified as primo infected were considered potential candidates for evolution into the severe form of malaria.
The MPV, PDW, and PCT values exhibited significant variability. A significant inverse relationship was observed between parasitaemia and PCT. Patients with warning signs for evolution into severe disease, with primo infection, or presenting with symptoms for over three days had the highest MPV and PDW. The mean platelet count was 114,823 ± 76,761 cells/mm3; 16.7% of the patients exhibited counts fewer than 50,000/mm3 and 60.7% had platelet counts between 50,000/mm3 and 150,000/mm3. The mean MPV was 9.3 µm, the mean PDW was 17.5% and mean PCT was 0.104%. Potentially more serious cases, that is, primo-infected patients, exhibited significantly higher MPV and PDW.
The authors concluded that that platelet indices were altered during acute and symptomatic infection by P. vivax. The elevation of MPV and PDW, and reduction of PCT are related to known potential risk factors for evolution into severe malaria, such as primo infection, longer symptom duration, and the presence of the classical warning signs of severe and complicated P. falciparum malaria. Therefore, these parameters and indices could be useful as predictors of severity in the clinical approach of patients with malaria caused by P. vivax. The study was published on December 27, 2013, in the Malaria Journal.
Related Links:
University Hospital of Federal University of Mato Grosso
Horiba Medical
Latest Hematology News
- Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
- Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
- Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
- Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
- Advanced CBC-Derived Indices Integrated into Hematology Platforms
- Blood Test Enables Early Detection of Multiple Myeloma Relapse
- Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
- Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
- Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
- New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
- Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
- AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
- Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
Channels
Clinical Chemistry
view channel
Urine-Based Test Shows Promise for Autism Screening in Children
Autism spectrum disorder (ASD) is commonly diagnosed through behavioral assessments, which can involve long waits that delay intervention. Earlier identification is linked to better developmental outcomes,... Read more
Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read moreMolecular Diagnostics
view channel
Blood-Based MRD Monitoring Supports Relapse Prevention in Leukemia
In myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), molecular blood testing for minimal residual disease (MRD) can detect signs of impending relapse before clinical symptoms emerge.... Read more
Genomic Test Predicts Chemotherapy Benefit in Metastatic Prostate Cancer
Metastatic prostate cancer remains a major treatment challenge, particularly when deciding whether to add chemotherapy to hormonal therapy. In the United States, about 334,000 men are diagnosed with prostate... Read moreImmunology
view channel
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
Tertiary lymphoid structures are emerging as important indicators of antitumor immunity, but their heterogeneity and spatial context within tumors remain difficult to capture through routine diagnostics.... Read more
AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel








